- Home
- NMZ vs NVCR Comparison
NMZ vs NVCR Comparison
Compare NMZ & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMZ | NVCR |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | NMZ | NVCR |
|---|---|---|
| Price | $10.25 | $12.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.08 |
| AVG Volume (30 Days) | 409.8K | ★ 981.7K |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | ★ 5.08% | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | N/A | $7.72 |
| Revenue Next Year | N/A | $6.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $9.83 | $9.82 |
| 52 Week High | $10.77 | $20.05 |
Technical Indicators
Market Signals| Indicator | NMZ | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 42.53 | 52.05 |
| Support Level | $10.00 | $10.72 |
| Resistance Level | $10.70 | $13.30 |
| Average True Range (ATR) | 0.09 | 0.58 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 1.20 | 63.54 |
Price Performance
Historical ComparisonAbout NMZ Nuveen Municipal High Income Opportunity Fund $0.01 par value per share
Nuveen Municipal High Income Opp Fund is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide high current income exempt from regular federal income tax. The Fund's secondary investment objective is to seek an attractive total return consistent with its primary objective.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.